Author:
Waterson Alex G.,Stevens Kirk L.,Reno Michael J.,Zhang Yue-Mei,Boros Eric E.,Bouvier Frederic,Rastagar Abdullah,Uehling David E.,Dickerson Scott H.,Reep Bryan,McDonald Octerloney B.,Wood Edgar R.,Rusnak David W.,Alligood Krystal J.,Rudolph Sharon K.
Subject
Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry
Reference13 articles.
1. Protein tyrosine kinase inhibitors as anticancer agents
2. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell lung cancer
3. Dual Kinase Inhibition in the Treatment of Breast Cancer: Initial Experience with the EGFR/ErbB-2 Inhibitor Lapatinib
4. Untangling the ErbB signalling network
5. Gomez, H. L. et al. A Phase II, Randomized Trial Using the Small Molecule Tyrosine Kinase Inhibitor Lapatinib as a First-Line Treatment in Patients with FISH Positive Advanced or Metastatic Breast Cancer, 41st Annual Meeting of the American Society for Clinical Oncologists, Orlando, FL, May 14–17, 2005; Abstract 3046. See also Abstracts 4594 and 3583.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献